Best Alternative to Noom Med for GLP-1: What to Look For (2026) | Luma Health
Provider Comparison · 2026

Best Alternative to
Noom Med for GLP-1

Quick Verdict

Noom Med's biggest cost driver for most patients is the bundled behavioral-coaching app, not the medication itself. A focused alternative that separates the two is often the more efficient path.

Luma Health's flat semaglutide ($197/month) and tirzepatide ($297/month) don't require an app subscription.

Patients researching Noom Med alternatives are usually looking for one of two things: a lower total cost, or a provider that doesn't require them to also engage with an app-based coaching program they may not want. Here's what to look for.

Why Patients Look for Alternatives

Noom Med bundles GLP-1 prescribing with Noom's behavioral coaching app, with combined pricing commonly reported in the $199-$399+/month range depending on medication, dose, and plan commitment. There's typically no option to access just the medication without the app layer, which is the main friction point for patients who don't specifically want or use that coaching feature.

What to Look for in an Alternative

A good alternative should offer: a real medical evaluation and ongoing provider access as the core of the price (not an add-on), flat pricing that doesn't rise with dose, transparency about which licensed pharmacy prepares the medication, and no requirement to subscribe to features you won't use.

You Don't Have to Choose Between Medication and Coaching

If you specifically want Noom's behavioral coaching app, you can typically keep that as a standalone subscription (or use any other tracking/coaching tool you prefer) while getting your medication from a focused, lower-cost provider. This decoupled approach often costs less overall than the bundled Noom Med price while still giving you both pieces.

The Cost Difference

Luma Health's compounded semaglutide is $197/month and tirzepatide is $297/month, flat, with your medical evaluation, provider visits, and shipping included — no app subscription bundled in. Compared to Noom Med's combined pricing, that's typically a meaningful monthly savings for patients who don't specifically need the behavioral coaching layer.

Which Fits You

Noom Med may still fit if you…
  • Already use and value Noom's coaching app
  • Want structured daily behavioral lessons alongside medication
  • Are comfortable with the bundled premium
A focused alternative fits if you…
  • Want medical care without an app subscription requirement
  • Prefer choosing your own tracking or coaching tools separately
  • Want the lowest predictable monthly total

Medical care,
no app required

Compounded semaglutide at $197/month or tirzepatide at $297/month — medical evaluation, provider visits, and shipping all included.

Get Started → Or start your free health assessment

Frequently Asked Questions

Generally no — Noom Med's model bundles the prescription with app access, without a medication-only option.

Cost is the most common reason, since the bundled app subscription adds a meaningful premium on top of medication cost for patients who don't specifically use the coaching features.

In some cases, yes — Noom's coaching app has been available as a standalone subscription separate from the GLP-1 program. Confirm current availability directly with Noom.

No. The active ingredient and clinical mechanism are the same regardless of which platform prescribes it. What differs is pricing structure and whether coaching is bundled in.

Depending on your current Noom Med tier, savings have been reported in the range of $50-$200+/month by choosing a focused, flat-rate alternative instead.

Not if you share your current dose and treatment history with your new provider during intake, which lets them continue your treatment plan without unnecessary retitration.

References

  1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
  3. U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
Medical Disclaimer: This article is for educational purposes and is not a substitute for professional medical advice. Individual results and needs vary; consult a licensed healthcare provider before starting, stopping, or changing any treatment or supplement. This article reflects information available as of July 2026. Luma Health's compounded medications are not themselves FDA-approved as finished drug products; their active ingredients are FDA-approved in commercial formulations such as Ozempic, Wegovy, Mounjaro, and Zepbound.